Wells Fargo & Company MN Grows Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

Wells Fargo & Company MN boosted its holdings in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 50.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 48,670 shares of the company's stock after buying an additional 16,357 shares during the period. Wells Fargo & Company MN's holdings in Privia Health Group were worth $951,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in PRVA. First Horizon Advisors Inc. boosted its stake in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock valued at $35,000 after buying an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Privia Health Group by 7,833.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after acquiring an additional 2,350 shares during the last quarter. Financial Management Professionals Inc. bought a new stake in shares of Privia Health Group in the 4th quarter valued at approximately $51,000. Nisa Investment Advisors LLC boosted its holdings in shares of Privia Health Group by 185.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock worth $98,000 after purchasing an additional 3,249 shares during the period. Finally, KBC Group NV increased its position in shares of Privia Health Group by 48.1% during the 4th quarter. KBC Group NV now owns 5,012 shares of the company's stock valued at $98,000 after purchasing an additional 1,627 shares during the last quarter. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Parth Mehrotra sold 15,100 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $352,283.00. Following the sale, the chief executive officer now owns 454,281 shares in the company, valued at approximately $10,598,375.73. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David Mountcastle sold 5,630 shares of the business's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the sale, the chief financial officer now owns 179,676 shares in the company, valued at $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,484 shares of company stock valued at $799,163. 10.70% of the stock is currently owned by company insiders.

Privia Health Group Stock Performance

Shares of PRVA stock traded down $0.07 on Monday, hitting $23.25. 13,838 shares of the stock traded hands, compared to its average volume of 767,852. The firm's 50-day moving average price is $23.50 and its two-hundred day moving average price is $22.12. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $26.04. The stock has a market capitalization of $2.82 billion, a PE ratio of 231.71, a PEG ratio of 3.47 and a beta of 0.88.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PRVA. JMP Securities reissued a "market outperform" rating and issued a $29.00 price objective on shares of Privia Health Group in a research report on Monday, April 28th. Canaccord Genuity Group lifted their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a report on Friday, February 28th. Robert W. Baird upped their target price on Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, April 15th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 price target on shares of Privia Health Group in a report on Thursday, April 10th. Finally, Barclays upped their price objective on Privia Health Group from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Privia Health Group currently has a consensus rating of "Buy" and an average target price of $27.38.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.